ArticleDermatology and therapy2026

Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results.

Michael Cecchini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.